FINWIRES · TerminalLIVE
FINWIRES

加拿大帝国商业银行将CGI的目标股价下调5加元,维持中性评级

By

-- 加拿大帝国商业银行资本市场(CIBC Capital Markets)维持对CGI(GIB-A.TO)股票的“中性”评级,但周三将目标股价从112加元下调至107加元。此前,该公司公布了第二季度业绩。 CIBC在4月29日的一份报告中表示:“我们惊讶地看到,在营收低于预期2%,调整后息税前利润(EBIT)和调整后每股收益(EPS)符合预期之后,该股今日出现两位数下跌。”报告指出,欧洲决策延迟的负面消息“逐渐显现”,且订单量同比下降4%,CIBC预计这可能会影响市场情绪。 “我们预计第二财季有机营收同比下降3.6%,较上季度4.5%的同比降幅有所改善,但低于去年同期0.4%的增幅。由于人工智能颠覆性风险持续对CGI构成威胁,我们仍持观望态度。但我们认为,政府支出增加、人工智能集成知识产权增长速度超出预期以及并购活动将带来利好。我们维持‘中性’评级,并将目标价从112美元下调至107美元,原因是略微下调了营收预期,以反映需求环境的逐步疲软。”CGI总结道。 CIBC指出,CGI在欧洲的决策有所延迟。该公司表示,德国经济疲软、芬兰政府订单减少以及法国制造业需求不明朗是造成这一现象的原因。CIBC预计,中东冲突也是一个因素,受影响的垂直行业(包括制造业和航空业)的需求存在不确定性,硬件供应链也受到一定影响。 CGI还指出,其增长点包括管理服务业务、政府和金融服务垂直领域,以及知识产权和人工智能主导的项目。 加拿大帝国商业银行(CIBC)指出,CGI在美国联邦政府市场的前景好于预期;CGI正在利用人工智能降低知识产权开发成本和缩短开发周期;并且CGI的资本配置重点仍然是内部投资(包括人工智能)、并购和股票回购。

Price: $88.27, Change: $-1.51, Percent Change: -1.68%

Related Articles

Mining & Metals

Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share

$AEM.TO
Treasury

TD Bank Group Issues 150 Million Swiss francs Green Bond

Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.

$TD$TD.TO
Research

Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.

$AMGN